PL448078A1 - Koniugat do stosowania w profilaktyce i leczeniu infekcji wywoływanych przez wirusa opryszczki pospolitej typu pierwszego - Google Patents

Koniugat do stosowania w profilaktyce i leczeniu infekcji wywoływanych przez wirusa opryszczki pospolitej typu pierwszego

Info

Publication number
PL448078A1
PL448078A1 PL448078A PL44807824A PL448078A1 PL 448078 A1 PL448078 A1 PL 448078A1 PL 448078 A PL448078 A PL 448078A PL 44807824 A PL44807824 A PL 44807824A PL 448078 A1 PL448078 A1 PL 448078A1
Authority
PL
Poland
Prior art keywords
herpes simplex
simplex virus
virus type
conjugate
prevention
Prior art date
Application number
PL448078A
Other languages
English (en)
Inventor
Joanna Kozieł
Anna GOLDA
Ewelina Dobosz
Marta Wadowska
Paulina KOSIKOWSKA-ADAMUS
Original Assignee
Uniwersytet Jagielloński
Uniwersytet Gdański
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński, Uniwersytet Gdański filed Critical Uniwersytet Jagielloński
Priority to PL448078A priority Critical patent/PL448078A1/pl
Publication of PL448078A1 publication Critical patent/PL448078A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ujawniono związek nadający się do stosowania w zapobieganiu lub leczeniu infekcji wywoływanych przez wirusa opryszczki pospolitej typu pierwszego (HSV-1).
PL448078A 2024-03-22 2024-03-22 Koniugat do stosowania w profilaktyce i leczeniu infekcji wywoływanych przez wirusa opryszczki pospolitej typu pierwszego PL448078A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL448078A PL448078A1 (pl) 2024-03-22 2024-03-22 Koniugat do stosowania w profilaktyce i leczeniu infekcji wywoływanych przez wirusa opryszczki pospolitej typu pierwszego

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL448078A PL448078A1 (pl) 2024-03-22 2024-03-22 Koniugat do stosowania w profilaktyce i leczeniu infekcji wywoływanych przez wirusa opryszczki pospolitej typu pierwszego

Publications (1)

Publication Number Publication Date
PL448078A1 true PL448078A1 (pl) 2025-09-29

Family

ID=97171694

Family Applications (1)

Application Number Title Priority Date Filing Date
PL448078A PL448078A1 (pl) 2024-03-22 2024-03-22 Koniugat do stosowania w profilaktyce i leczeniu infekcji wywoływanych przez wirusa opryszczki pospolitej typu pierwszego

Country Status (1)

Country Link
PL (1) PL448078A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763406A (en) * 1991-02-25 1998-06-09 Carlbiotech, Ltd. A/S Method for the treatment of conditions caused by herpes virus infections
US20150093825A1 (en) * 2010-09-16 2015-04-02 The Board Of Trustees Of The University Of Illinois Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763406A (en) * 1991-02-25 1998-06-09 Carlbiotech, Ltd. A/S Method for the treatment of conditions caused by herpes virus infections
US20150093825A1 (en) * 2010-09-16 2015-04-02 The Board Of Trustees Of The University Of Illinois Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARCOCCI ME, AMATORE D, VILLA S, CASCIARO B, AIMOLA P, FRANCI G, ET AL.: "(2018) 62(5):1–13.", THE AMPHIBIAN ANTIMICROBIAL PEPTIDE TEMPORIN B INHIBITS IN VITRO HERPES SIMPLEX VIRUS 1 INFECTION. ANTIMICROB AGENTS CHEMOTHER. *
MARCOCCI ME, JACKOWSKA BG, PREZIOSO C, PROTTO V, DE ANGELIS M, DI LEVA FS, ET AL.: "(2022) 23(13):1–15.", THE INHIBITION OF DNA VIRUSES BY THE AMPHIBIAN ANTIMICROBIAL PEPTIDE TEMPORIN G: A VIROLOGICAL STUDY ADDRESSING HSV-1 AND JPCYV. INT J MOL SCI. *

Similar Documents

Publication Publication Date Title
NO934556L (no) Absorberende gjenstand med festeanordning som gir elastisk dynamisk livbåndpasning
ES2151897T3 (es) Benzoxazinonas como inhibidores de la transcriptasa inversa de vih.
PE43897A1 (es) Derivados de quinazolina
ATE476984T1 (de) Behandlung von herpes infektion mit anwendung von immunomodulatore polynukleotide sequenzen
ES2125251T3 (es) Inhibidores de la proteasa del vih.
ES2180633T3 (es) Uso de derivados de pteridina como inhibidores de la no-sintasa.
IL118075A0 (en) Alpha-substituted pyrimidine-thioalkyl and alkylether compounds
BR0207752A (pt) Composto, sais de sódio, cálcio, potássio, magnésio, colina, etanolamina e trietilamina dos compostos, formas dos mesmos, métodos de tratamento ou de prevenção de uma infeção viral em um ser humano e de tratamento dos vìrus mutantes hiv uso de um composto, composição farmacêutica, e, processo para a preparação dos compostos
ES2096455T3 (es) Aplicacion de la lamotrigina en el tratamiento del neurosida.
DK0752813T3 (da) Hæmmere af metozoan-parasit-proteaser
MX9308025A (es) Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
PL448078A1 (pl) Koniugat do stosowania w profilaktyce i leczeniu infekcji wywoływanych przez wirusa opryszczki pospolitej typu pierwszego
GR3029370T3 (en) Compounds and methods for inhibition of hiv and related viruses
ZA991029B (en) Composition and methods for treatment of hiv infections.
ATE150317T1 (de) Synergische mischung zur behandlung von herpes
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
PT838223E (pt) Inibidor do edema cerebral
BR9912004A (pt) Oxazolidinonas para tratar infecções dos olhos
EP0906111A4 (en) COMPOSITION AND METHOD FOR TREATING HERPES SIMPLEX
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
MX2022011138A (es) Efecto contra coronavirus y aplicacion de inhibidor de fosfatidilinositol 4-cinasa.
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DOP2002000449A (es) Sal sodica de un inhibidor de integradasa del vih.